5-bromo-3-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1314883-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-3-(4-(methylsulfonyl)phenyl)pyridin-2-amine
• 英文别名: 5-Bromo-3-(4-methylsulfonylphenyl)pyridin-2-amine
• CAS: 1314883-38-9
• 化学式: C₁₂H₁₁BrN₂O₂S
• 分子量: 327.202
• InChiKey: GQAOHPCZUKXASH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  81.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-bromo-3-(4-(methylsulfonyl)phenyl)pyridin-2-amine 、 4-羟基苯硼酸 在 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以78%的产率得到4-(6-amino-5-(4-(methylsulfonyl)phenyl)pyridin-3-yl)phenol
  参考文献：
  名称：

  Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment

  摘要：

  Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of concept in vivo. The medicinal chemistry effort that led to the discovery of these lead compounds is described herein together with in vivo pharmacokinetic properties and activity in a model of insulin resistance.

  DOI：

  10.1021/acsmedchemlett.5b00215
• 作为产物：
  描述：

  2-氨基-5-溴-3-碘吡啶 、 4-（甲磺酰基）苯硼酸 在 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 4.0h， 以64%的产率得到5-bromo-3-(4-(methylsulfonyl)phenyl)pyridin-2-amine
  参考文献：
  名称：

  Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment

  摘要：

  Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of concept in vivo. The medicinal chemistry effort that led to the discovery of these lead compounds is described herein together with in vivo pharmacokinetic properties and activity in a model of insulin resistance.

  DOI：

  10.1021/acsmedchemlett.5b00215

文献信息

• NEW ANTI-MALARIAL AGENTS
  申请人：Witty Michael John

  公开号：US20120295905A1

  公开（公告）日：2012-11-22

  The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

  本发明涉及氨基吡啶衍生物在制造预防或治疗疟疾药物方面的用途。具体而言，本发明涉及氨基吡啶衍生物，可用于制备制药配方，以抑制疟原虫的增殖。
• US9024033B2
  申请人：——

  公开号：US9024033B2

  公开（公告）日：2015-05-05
• [EN] NEW ANTI-MALARIAL AGENTS<br/>[FR] NOUVEAUX AGENTS ANTIPALUDIQUES
  申请人：MEDICINES FOR MALARIA VENTURE MMV

  公开号：WO2011086531A2

  公开（公告）日：2011-07-21

  The present invention is related to a use of aminopyridine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyridine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.
• Discovery of an <i>in Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment
  作者：Mark Ammirati、Scott W. Bagley、Samit K. Bhattacharya、Leonard Buckbinder、Anthony A. Carlo、Rebecca Conrad、Christian Cortes、Robert L. Dow、Matthew S. Dowling、Ayman El-Kattan、Kristen Ford、Cristiano R. W. Guimarães、David Hepworth、Wenhua Jiao、Jennifer LaPerle、Shenping Liu、Allyn Londregan、Paula M. Loria、Alan M. Mathiowetz、Michael Munchhof、Suvi T. M. Orr、Donna N. Petersen、David A. Price、Athanasia Skoura、Aaron C. Smith、Jian Wang

  DOI：10.1021/acsmedchemlett.5b00215

  日期：2015.11.12

  Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of concept in vivo. The medicinal chemistry effort that led to the discovery of these lead compounds is described herein together with in vivo pharmacokinetic properties and activity in a model of insulin resistance.